Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 6Completed 6Active not recruiting 5Withdrawn 3Unknown 3Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 18Leukemia, Lymphocytic, Chronic, B-Cell 6Lymphoma, Follicular 5Recurrence 4Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma 3Waldenstrom Macroglobulinemia 2Neoplasms, Plasma Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Leukemia 2Sezary Syndrome 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Neoplasm, Residual 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Immunoblastic 1Leukemia, Plasma Cell 1Leukemia, Hairy Cell 1Intraocular Lymphoma 1Hematologic Neoplasms 1Hematologic Diseases 1Burkitt Lymphoma 1Blood Protein Disorders 1

Interventions

Cisplatin 9pembrolizumab 7Radiosurgery 6Gemcitabine 6Paclitaxel 5Dexamethasone 5Taxes 4Carboplatin 4trametinib 3ibrutinib 3Surveys and Questionnaires 3Standard of Care 3Radiotherapy 3Nivolumab 3Magnetic Resonance Spectroscopy 3Lenalidomide 3Fluorouracil 3Erlotinib Hydrochloride 3Blood Specimen Collection 3Ascorbic Acid 3venetoclax 2veliparib 2tocilizumab 2pazopanib 2obinutuzumab 2naquotinib 2lenvatinib 2fludarabine 2enzalutamide 2Vemurafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Neoplasms × Lenalidomide × Clear all
NCT03785184 2019-08-28

A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy

AbbVie

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Neoplasms

NCT02155634 2018-04-10

Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma

Celgene

Phase 3 Withdrawn
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias

NCT02371590 2018-02-23

Lenalidomide and Obinutuzumab for Previously Untreated CLL

University of California, San Diego

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡